Scinai regains Nasdaq compliance, eyes EIB loan conversion By Investing.com

JERUSALEM – Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biotech company specializing in inflammation and immunology products, has regained compliance with Nasdaq’s minimum bid price requirement. On Monday, the company received notification from Nasdaq that its American Depositary Shares (ADSs) had maintained a closing bid price of at least $1.00 for ten consecutive business days following a ratio change effective May 21, 2024.

The company had previously reported noncompliance with Nasdaq’s bid price rule, prompting a ratio change that increased the number of ordinary shares each ADS represents from 400 to 4,000. This adjustment successfully elevated the bid price above the minimum threshold.

Despite this progress, Scinai remains non-compliant with Nasdaq’s minimum shareholders’ equity requirement. The company has disclosed ongoing discussions with the European Investment Bank (EIB) to amend their finance contract, potentially converting a significant portion of the loan into equity. This conversion is intended to be a central element of the compliance plan Scinai will present to a Nasdaq Hearings Panel on June 18, 2024. The terms of the agreement are still under negotiation and subject to EIB’s formal approval.

Scinai operates two business units: one focused on developing biological therapeutic products for diseases with unmet medical needs, and Scinai Bioservices, which provides Contract Development and Manufacturing Organization (CDMO) services. The company’s efforts to regain full compliance with Nasdaq’s listing rules are ongoing, and the outcome of the scheduled hearing will be crucial in determining its continued listing status.

In other recent news, Scinai Immunotherapeutics Ltd. is striving to maintain its Nasdaq listing amid equity compliance challenges. The biopharmaceutical company received a second notification from Nasdaq, indicating a failure to meet the minimum stockholders’ equity requirement for continued listing.

To address non-compliance with Nasdaq’s minimum bid price rule, Scinai has executed a strategic change in its share structure, a reverse split, increasing the number of ordinary shares each American Depositary Share represents.

In another development, Scinai has scheduled a hearing with the Nasdaq Hearings Panel where it aims to present a plan to regain compliance. This plan may include converting a portion of the company’s loan from the European Investment Bank into equity. However, this move relies on formal approval from the Bank and the fulfillment of any preceding conditions.

InvestingPro Insights

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) has shown resilience in its stock price, recently achieving a noteworthy 10.64% return over the past week. This positive performance comes as a glimmer of hope amidst a challenging financial landscape for the company. According to the latest data from InvestingPro, SCNI’s market capitalization stands at a modest $1.81 million, reflecting the scale of the company in the competitive biotech industry.

InvestingPro Tips for SCNI paint a picture of a company that is grappling with financial challenges, including a significant debt burden and a rapid cash burn rate. These insights underscore the importance of the ongoing negotiations with the European Investment Bank and the potential equity conversion as critical steps for the company’s financial restructuring. With liquid assets exceeding short-term obligations, SCNI shows some capacity to meet immediate financial commitments, a crucial factor as it seeks to maintain compliance with Nasdaq’s requirements.

However, the company’s valuation suggests concerns, as indicated by a negative price-to-earnings (P/E) ratio of -0.28 for the last twelve months as of Q4 2023. This metric, along with a negative price-to-book ratio of -0.4, hints at market skepticism about the company’s current financial health and future prospects. Moreover, the absence of dividend payments to shareholders may limit the stock’s attractiveness to income-focused investors, aligning with the company’s focus on addressing its capital structure and operational challenges.

For investors seeking a deeper dive into SCNI’s financials and strategic positioning, InvestingPro offers additional insights and metrics. By using the promo code PRONEWS24, investors can receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription, accessing a wealth of InvestingPro Tips that can further inform investment decisions. Currently, there are 9 additional tips listed on InvestingPro for SCNI, providing a comprehensive analysis of the company’s performance and outlook.

As Scinai Immunotherapeutics continues its efforts to meet Nasdaq’s listing requirements and secure its financial future, these InvestingPro Insights and Tips could prove invaluable for investors monitoring the company’s progress.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.